Asia-Pacific Point of Care Diagnostics Market Outlook, 2031
The Asia Pacific Point of Care Diagnostics Market is segmented into By Product (Glucose Monitoring Kits, Infectious Diseases Testing Kits, Pregnancy And Fertility Testing Kits, Hematology Testing Kits, Cardiometabolic Monitoring Kits, Urinalysis Testing Kits, Cholesterol Test Strips, Other Products); By Technology/Platform (Lateral Flow Assays, Molecular Diagnostics (PCR/INAAT), Microfluidics & Immunoassays, Dipsticks & Test Strips); By End-User (Hospitals & Critical Care Centers, Clinical & Diagnostic Laboratories, Home Care & Self-Testing); By Mode Of Purchase (Prescription Based Products, OTC Products); By Sample (Blood, Urine, Nasal and Oropharyngeal Swabs).
- Bonafide Research
- 23-09-2026
- Pages : 97
- Figures : 8
- Tables : 25
- Region : Asia-Pacific
- Category : Lifescience & Healthcare
- Medical Devices
- Schedule a Call
-
Sikandar Kesari — Research Analyst
The Asia Pacific Point of Care Diagnostics Market is anticipated to grow at more than 9.15% CAGR from 2026 to 2031, driven by the growing demand for rapid and convenient testing.
- Historical Period2020-2024
- Base Year2025
- Forecast Period2026-2031
- CAGR (2026-2031) 9.15%
- Largest MarketChina
- Fastest Market India
- Format
Featured Companies
- 1. Abbott Laboratories
- 2. Danaher
- 3. F. Hoffmann-La Roche AG,
- 4. Siemens Healthineers
- 5. OraSure Technologies
- 6. Thermo Fisher Scientific Inc
- More...
Point of Care Diagnostics Market Analysis
The Asia Pacific Point-of-Care (POC) Diagnostics market represents medical testing conducted directly at or near patient care sites such as rural clinics, urban hospitals, retail pharmacies, and home environments delivering rapid diagnostic feedback without reliance on centralized laboratories. Expanding as the world's fastest-growing regional market, it is driven by a high prevalence of chronic conditions like diabetes, recurring infectious disease outbreaks, rapidly aging populations in China and Japan, and aggressive public healthcare investments across emerging economies like India and Southeast Asia. Crucial to regional healthcare modernization, POC testing bridges severe clinical infrastructure gaps in rural and remote areas, reduces diagnostic turnaround times from days to minutes, relieves hospital overcrowding, and lowers overall treatment costs. Key regional organizations such as the Asian Pacific Federation of Clinical Biochemistry and Laboratory Medicine (APFCB) and the Asia-Pacific Medical Technology Association (APACMed) actively support industry growth by establishing standardized quality controls, harmonizing cross-border regulatory frameworks, and advocating for broader reimbursement coverage. Current market activities center on deploying low-cost microfluidic lab-on-a-chip platforms, expanding smartphone-connected digital biosensors for remote patient monitoring, localizing supply chain manufacturing to overcome import dependencies, and launching community-based screening initiatives for early cancer and cardiovascular risk detection. Concurrently, local diagnostic manufacturers are scaling up domestic manufacturing of cost-effective test strips and portable analyzers, significantly reducing dependence on expensive Western imports. Finally, rapid digital adoption across the region is fostering integration between mobile-connected biosensors and regional health-tech platforms, enabling real-time diagnostic data transmission for widespread remote patient monitoring in rural communities. According to the research report, " Asia Pacific Point of Care Diagnostics Market Outlook, 2031," published by Bonafide Research, the Asia Pacific Point of Care Diagnostics Market is anticipated to grow at more than 9.15% CAGR from 2026 to 2031.The Asia Pacific Point-of-Care (POC) Diagnostics market represents rapid, decentralized clinical testing performed at or near patient care sites such as rural primary health centers, hospital bedsides, community pharmacies, and home environments eliminating delays from centralized lab processing. Prominent multinationals like Abbott Laboratories, Roche, Siemens Healthineers, and Danaher dominate the landscape, alongside rapidly growing regional leaders such as Nipro Corporation (Japan) and Mindray (China). Major opportunities lie in developing low-cost paper biosensors, smartphone-integrated microfluidics, and multiplex respiratory panels tailored for tropical and infectious disease management. Key industry developments highlight regional expansion, including Mindray launching automated point-of-care immunoassay systems, Roche partnering with local Asian health tech platforms for cloud-based diabetes management, and Abbott expanding localized manufacturing of rapid infectious disease test kits across Southeast Asia. Supply chain analysis reveals a two-tiered regional ecosystem: high-precision microfluidics and electronic analyzers are primarily produced in advanced industrial hubs like Japan, South Korea, and Singapore, while mass manufacturing of plastic assay cartridges, lateral-flow test strips, and biological reagents is concentrated in China and India. To overcome historical supply chain disruptions, logistics bottlenecks, and import reliance, major companies are increasingly nearshoring production, forging strategic distribution partnerships with regional medical suppliers, and establishing localized cold-chain networks to ensure uninterrupted delivery across diverse geographic markets.
to Download this information in a PDF
What's Inside a Bonafide Research`s industry report?
A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.
Download SampleMarket Dynamics
Market Drivers
• Massive chronic disease burden combined with rapid population aging: The Asia-Pacific region is home to the world’s largest diabetic population with China and India accounting for over 200 million diabetic adults combined alongside rapidly aging societies in countries like Japan, South Korea, and urban China. Managing chronic conditions across these vast populations requires continuous, decentralized diagnostic monitoring for blood glucose, HbA1c, cardiac biomarkers, lipid panels, and kidney function. Point-of-care testing enables frequent monitoring without overloading central hospital laboratories, allowing clinicians and patients to make immediate therapeutic adjustments.• Government infrastructure initiatives to bridge urban-rural healthcare disparities: A defining characteristic of the APAC market is the stark contrast between advanced urban medical centers and resource-constrained rural communities. To address these inequities, regional governments are funding national diagnostic access programs (e.g., India’s Ayushman Bharat health centers and China’s rural healthcare expansion drives).
Market Challenges
• Extreme regulatory fragmentation and protracted local approval cycles: Operating across the Asia-Pacific region requires navigating a patchwork of distinct national regulatory frameworks. Unlike the EU's unified IVDR system, medical device manufacturers must secure individual regulatory clearances from separate national authorities such as China’s NMPA, India’s CDSCO, Japan’s PMDA, and Australia’s TGA. Each agency maintains its own clinical trial requirements, local testing standards, and administrative procedures.• Price sensitivity, low reimbursement coverage, and out-of-pocket cost barriers: While East Asian nations like Japan and South Korea offer comprehensive public health insurance coverage, emerging economies across South and Southeast Asia rely heavily on out-of-pocket healthcare expenditure by patients. High-tech POC analyzers especially microfluidic cartridges and sample-to-answer molecular PCR platforms carry high manufacturing costs relative to standard central lab testing.
Market Trends
• Localization of manufacturing and growth of regional domestic MedTech champions: Historically reliant on Western medical imports from North America and Europe, the APAC region is undergoing a strong shift toward domestic diagnostic manufacturing. Driven by government policies promoting local production (e.g., India’s Production Linked Incentive scheme and China’s "Buy Local" healthcare mandates), regional enterprises such as Mindray, Sansure Biotech, and Nipro Corporation are aggressively expanding their manufacturing capabilities.• Smartphone-connected biosensors, digital health platforms, and telemedicine integration: Asia-Pacific leads global rates of mobile connectivity and digital payment adoption, creating a fertile ecosystem for smartphone-integrated point-of-care diagnostics. Modern POC devices across APAC are increasingly built to pair with mobile phones via micro-USB, Bluetooth, or optical camera readers. These connected biosensors transform standard smartphones into diagnostic readers capable of analyzing test strips, processing data through cloud-based diagnostic algorithms, and transmitting real-time results directly to electronic medical registries or regional telemedicine apps.
Point of Care Diagnostics Segmentation
| By Product | Glucose Monitoring Kits | |
| Infectious Diseases Testing Kits | ||
| Pregnancy And Fertility Testing Kits | ||
| Hematology Testing Kits | ||
| Cardiometabolic Monitoring Kits | ||
| Urinalysis Testing Kits | ||
| Cholesterol Test Strips | ||
| Other Products | ||
| By Technology/Platform | Lateral Flow Assays | |
| Molecular Diagnostics (PCR/INAAT) | ||
| Microfluidics & Immunoassays | ||
| Dipsticks & Test Strips | ||
| By End-User | Hospitals & Critical Care Centers | |
| Clinical & Diagnostic Laboratories | ||
| Home Care & Self-Testing | ||
| Asia-Pacific | China | |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
Glucose monitoring kits are the largest product segment in Asia Pacific because the region has a very large diabetes burden and diabetes management increasingly depends on regular access to blood-glucose monitoring technologies. The importance of glucose monitoring kits in Asia Pacific is closely connected to the scale of diabetes and the need for repeated measurement during long-term disease management. WHO South-East Asia reports that hundreds of millions of adults in the region are living with diabetes, with a substantial proportion remaining undiagnosed or untreated, creating a major need for accessible diagnostic and monitoring services. WHO specifically identifies blood-glucose monitoring as an essential component of diabetes care and states that people with type 1 diabetes should have access to affordable blood-glucose self-monitoring. The need is not limited to diagnosis because glucose levels can change according to food intake, medication, physical activity, illness and other factors, making repeated measurements useful for treatment management. WHO’s 2025 review of diabetes technologies specifically includes blood-glucose meters, test strips and lancets among the technologies required for diabetes management, demonstrating their established role within healthcare systems. In South-East Asia, health authorities are also integrating diabetes screening and management into primary healthcare, while countries are strengthening access to essential medicines and glucose-monitoring devices. China provides an additional illustration of the scale of healthcare infrastructure available for chronic-disease services: official statistics recorded 1.092 million medical and health institutions and 39,000 hospitals by the end of 2024, alongside 10.11 billion medical visits during that year. China’s national diabetes-control programme also calls for stronger diabetes screening, primary-care management, annual glucose testing for specified high-risk groups, and improved testing capacity at grassroots healthcare facilities. Dipsticks and test strips are the largest technology/platform segment because their simple operating requirements, rapid results and ability to perform decentralized testing make them highly practical across the diverse healthcare environments of Asia Pacific. Dipsticks and test strips fit particularly well with the practical requirements of point-of-care diagnostics because they can often be used without the infrastructure associated with a centralized laboratory. Their value is especially relevant in Asia Pacific, where healthcare systems range from highly equipped tertiary hospitals to community facilities and geographically remote health posts. WHO’s 2025 guidance on rapid diagnostic test accessibility specifically includes urine dipsticks among the diagnostic formats considered for professional and self-testing environments. WHO also describes instrument-free diagnostics and self-tests as important categories for low- and middle-income settings, emphasizing operational characteristics that allow testing where laboratory resources are limited. A strip-based test can generally be transported and stored more easily than a large laboratory analyzer, while many applications require only a specimen, the test device and a simple interpretation process. This makes the format relevant for screening and preliminary assessment in primary-care facilities, pharmacies, community programmes and other decentralized locations. WHO’s Western Pacific laboratory programme is actively supporting the adoption of rapid tests and point-of-care testing, including work aimed at expanding diagnostic capacity and using mobile or decentralized technologies. The technology also covers several clinical areas rather than being limited to a single disease. WHO’s rapid diagnostic accessibility guidance includes urine dipsticks, pregnancy tests, G6PD testing and infectious-disease rapid tests among relevant applications. Lateral-flow and strip-based formats have also demonstrated usefulness in infectious-disease testing; WHO notes that visually interpreted rapid diagnostic tests can be used at lower levels of healthcare and in self-testing settings. Asia Pacific has particularly strong practical reasons for decentralized testing because remote communities, islands, rural districts and densely populated urban areas can all present different access challenges. Hospitals and critical care centers are the largest end-user segment because they concentrate high patient volumes and clinical situations where rapid diagnostic information is required to support immediate treatment and monitoring. Hospitals and critical-care facilities naturally generate substantial demand for point-of-care diagnostics because they manage patients with acute illnesses, complex chronic conditions, trauma, infections and rapidly changing physiological conditions. Point-of-care testing is particularly useful when diagnostic information is required during the patient encounter rather than after specimens have been transported to a distant laboratory. WHO’s Western Pacific diagnostic-stewardship guidance emphasizes selecting the right test, patient, specimen and timing so that diagnostic information can directly support clinical management. Asia Pacific’s hospital infrastructure provides a very large base for this type of testing. China alone had 39,000 hospitals and more than 8.18 million hospital beds at the end of 2024, according to official national statistics, while hospitals recorded billions of patient visits during the year. The volume and variety of care delivered in such institutions create repeated situations in which rapid testing can be useful. Emergency departments may require immediate assessment of infectious conditions or metabolic abnormalities, while intensive-care environments can require serial measurements to monitor changes during treatment. Operating rooms and other high-acuity departments also benefit from diagnostic technologies that can provide information without waiting for conventional laboratory workflows. WHO’s Western Pacific region is additionally strengthening laboratory and point-of-care capabilities for outbreak detection, emergency diagnostics and decentralized testing, showing the continuing role of rapid diagnostic technologies in health-system preparedness. The role of hospitals is not limited to acute disease. Patients receiving treatment for diabetes, cardiovascular conditions, kidney disease and other chronic illnesses may undergo repeated diagnostic assessments during consultations, admissions and follow-up care. WHO’s diabetes programmes in South-East Asia specifically encourage stronger diagnostic capacity within primary care and closer coordination between hospitals and lower-level facilities, indicating that hospitals remain part of a broader diagnostic network. Point-of-care testing can also support infection-control and antimicrobial-resistance programmes by providing timely information about infectious diseases and helping clinicians select appropriate treatment. OTC products are the largest mode-of-purchase segment because consumer-accessible diagnostic products make selected tests available for use without requiring every testing episode to begin with a healthcare appointment. Over-the-counter point-of-care diagnostics have an important role in Asia Pacific because healthcare access differs considerably between countries, regions and population groups, making convenient testing formats valuable for selected conditions. WHO recognizes self-testing as an established diagnostic approach in which individuals collect a specimen, perform a rapid test and interpret the result themselves, with the objective of increasing access and uptake of testing services. The organization has supported self-testing approaches for HIV and other conditions and emphasizes that self-testing can decentralize services, increase patient autonomy and reduce some of the burden placed on facility-based testing. Asia Pacific already provides concrete examples of consumer-accessible rapid diagnostics. WHO has documented self-testing implementation in countries including India, Thailand, Malaysia, the Philippines, Nepal and Viet Nam, demonstrating that self-testing products have been introduced across multiple Asian healthcare environments. Glucose monitoring is another important example because blood-glucose meters and test strips are designed for repeated monitoring outside centralized laboratories. WHO’s South-East Asia guidance identifies access to blood-glucose self-monitoring as an important element of diabetes management, while its 2025 technology assessment specifically includes meters, test strips and lancets among diabetes-management technologies. OTC-style access is particularly useful when the purpose is routine monitoring, preliminary screening or self-testing rather than a complex diagnostic investigation requiring specialist interpretation. The practical advantages include convenient access, reduced travel for some routine measurements, the ability to test at a chosen time and the possibility of obtaining an immediate result. These characteristics are relevant in both large cities and areas where healthcare facilities are geographically distant. WHO’s target product profile for low- and middle-income settings specifically considers self-tests and instrument-free diagnostics as product categories requiring appropriate accessibility, usability and quality characteristics. Blood is the largest sample segment because it can be collected in small quantities and supports a broad range of point-of-care tests covering metabolic, infectious, hematological and critical-care applications. Blood is particularly valuable as a point-of-care specimen because a small sample can provide information about multiple physiological and disease-related parameters, and capillary blood can often be collected through a finger prick without conventional venous blood collection. This is especially important for glucose monitoring, which is a major point-of-care application across Asia Pacific. WHO identifies blood-glucose meters and test strips as essential technologies for diabetes management and specifically supports access to blood-glucose self-monitoring. Blood also has extensive applications beyond diabetes. WHO’s prequalification and diagnostic resources list whole blood as a specimen for several rapid tests, including malaria and syphilis testing, while other point-of-care applications use blood-derived specimens for infectious and biochemical assessments. This breadth gives blood an important advantage over sample types that are restricted to narrower diagnostic applications. In many settings, blood-based rapid tests can be performed close to the patient and provide information during the same healthcare encounter. WHO’s Western Pacific work emphasizes rapid and point-of-care testing as part of efforts to strengthen diagnostic capacity, including in remote and hard-to-reach communities. Finger-prick collection can also be practical where trained phlebotomy resources or conventional laboratory facilities are limited, provided the specific test has been validated for capillary blood and appropriate procedures are followed. The sample is relevant to both acute and chronic healthcare needs. Diabetes requires repeated glucose measurements, infectious diseases can require rapid pathogen or antibody testing, and some emergency or hospital tests depend on blood-based measurements to assess immediate physiological conditions. The breadth of use is reflected in WHO’s Essential Diagnostics List, which includes tests intended for point-of-care use in communities as well as laboratory environments.
to Download this information in a PDF
Point of Care Diagnostics Market Regional Insights
China is the largest country-level component of the Asia Pacific point-of-care diagnostics market because its exceptionally large healthcare system, extensive hospital network, high patient utilization and national emphasis on strengthening diabetes and primary-care diagnostics create a broad base for point-of-care testing. China has an unusually extensive healthcare infrastructure that provides numerous locations for point-of-care diagnostics, ranging from major hospitals to community and township facilities. Official Chinese statistics show that by the end of 2024 the country had 1.092 million medical and health institutions, including 39,000 hospitals, 37,000 community health service centers, 33,000 township health centers, 398,000 clinics and 571,000 village clinics. The same data recorded 10.11 billion medical visits during 2024 and more than 10 million healthcare beds nationally. This extensive network is important for point-of-care diagnostics because testing can be deployed at multiple levels rather than being confined to large tertiary hospitals. China has also strengthened primary healthcare capacity: official statistics indicate that grassroots medical institutions accounted for more than half of all medical visits in 2023, demonstrating the scale of care delivered outside hospitals. Diabetes is another major driver of diagnostic requirements. China’s national diabetes-prevention programme calls for stronger screening, improved testing capabilities in grassroots facilities, annual fasting-glucose testing for specified high-risk groups and closer coordination between hospitals and primary healthcare providers. These measures create a direct institutional need for accessible glucose and other point-of-care tests. China’s healthcare system also has substantial demand for rapid diagnostics related to infectious diseases, chronic conditions and emergency care. WHO’s Western Pacific programme is supporting countries in the region with rapid tests, point-of-care testing, mobile diagnostics and digital diagnostic systems, reflecting the broader regional movement toward decentralized testing. China is also an important participant in the diagnostic-device ecosystem: WHO’s prequalification resources list several Chinese manufacturers and products among rapid diagnostic technologies, including whole-blood and point-of-care tests.
to Download this information in a PDF
Companies Mentioned
- Abbott Laboratories
- Danaher
- F. Hoffmann-La Roche AG,
- Siemens Healthineers
- OraSure Technologies
- Thermo Fisher Scientific Inc
- QIAGEN N.V.
- QuidelOrtho Corporation
- Becton, Dickinson and Company
- bioMérieux
- EKF Diagnostics
- Werfen S.A.
Table of Contents
- 1. Executive Summary
- 2. Market Dynamics
- 2.1. Market Drivers & Opportunities
- 2.2. Market Restraints & Challenges
- 2.3. Market Trends
- 2.4. Supply chain Analysis
- 2.5. Policy & Regulatory Framework
- 2.6. Industry Experts Views
- 3. Research Methodology
- 3.1. Secondary Research
- 3.2. Primary Data Collection
- 3.3. Market Formation & Validation
- 3.4. Report Writing, Quality Check & Delivery
- 4. Market Structure
- 4.1. Market Considerate
- 4.2. Assumptions
- 4.3. Limitations
- 4.4. Abbreviations
- 4.5. Sources
- 4.6. Definitions
- 5. Economic /Demographic Snapshot
- 6. Asia-Pacific Point of Care Diagnostics Market Outlook
- 6.1. Market Size By Value
- 6.2. Market Share By Country
- 6.3. Market Size and Forecast, By Product
- 6.4. Market Size and Forecast, By Technology/Platform
- 6.5. Market Size and Forecast, By End-User
- 6.6. Market Size and Forecast, By Mode Of Purchase
- 6.7. Market Size and Forecast, By Sample
- 6.8. China Point of Care Diagnostics Market Outlook
- 6.8.1. Market Size by Value
- 6.8.2. Market Size and Forecast By Product
- 6.8.3. Market Size and Forecast By Technology/Platform
- 6.8.4. Market Size and Forecast By End-User
- 6.9. Japan Point of Care Diagnostics Market Outlook
- 6.9.1. Market Size by Value
- 6.9.2. Market Size and Forecast By Product
- 6.9.3. Market Size and Forecast By Technology/Platform
- 6.9.4. Market Size and Forecast By End-User
- 6.10. India Point of Care Diagnostics Market Outlook
- 6.10.1. Market Size by Value
- 6.10.2. Market Size and Forecast By Product
- 6.10.3. Market Size and Forecast By Technology/Platform
- 6.10.4. Market Size and Forecast By End-User
- 6.11. Australia Point of Care Diagnostics Market Outlook
- 6.11.1. Market Size by Value
- 6.11.2. Market Size and Forecast By Product
- 6.11.3. Market Size and Forecast By Technology/Platform
- 6.11.4. Market Size and Forecast By End-User
- 6.12. South Korea Point of Care Diagnostics Market Outlook
- 6.12.1. Market Size by Value
- 6.12.2. Market Size and Forecast By Product
- 6.12.3. Market Size and Forecast By Technology/Platform
- 6.12.4. Market Size and Forecast By End-User
- 7. Competitive Landscape
- 7.1. Competitive Dashboard
- 7.2. Business Strategies Adopted by Key Players
- 7.3. Porter's Five Forces
- 7.4. Company Profile
- 7.4.1. Abbott
- 7.4.1.1. Company Snapshot
- 7.4.1.2. Company Overview
- 7.4.1.3. Financial Highlights
- 7.4.1.4. Geographic Insights
- 7.4.1.5. Business Segment & Performance
- 7.4.1.6. Product Portfolio
- 7.4.1.7. Key Executives
- 7.4.1.8. Strategic Moves & Developments
- 7.4.2. F. Hoffmann-La Roche Ltd.
- 7.4.3. Siemens Healthineers AG
- 7.4.4. QuidelOrtho Corporation
- 7.4.5. Danaher
- 7.4.6. Becton, Dickinson and Company
- 7.4.7. Thermo Fisher Scientific
- 7.4.8. bioMérieux
- 7.4.9. EKF Diagnostics
- 7.4.10. QIAGEN
- 7.4.11. Werfen S.A.
- 7.4.12. OraSure Technologies
- 8. Strategic Recommendations
- 9. Annexure
- 9.1. FAQ`s
- 9.2. Notes
- 10. Disclaimer
Table 2: Top 10 Counties Economic Snapshot 2024
Table 3: Economic Snapshot of Other Prominent Countries 2022
Table 4: Average Exchange Rates for Converting Foreign Currencies into U.S. Dollars
Table 5: Asia-Pacific Point of Care Diagnostics Market Size and Forecast, By Product (2020 to 2031F) (In USD Billion)
Table 6: Asia-Pacific Point of Care Diagnostics Market Size and Forecast, By Technology/Platform (2020 to 2031F) (In USD Billion)
Table 7: Asia-Pacific Point of Care Diagnostics Market Size and Forecast, By End-User (2020 to 2031F) (In USD Billion)
Table 8: Asia-Pacific Point of Care Diagnostics Market Size and Forecast, By Mode Of Purchase (2020 to 2031F) (In USD Billion)
Table 9: Asia-Pacific Point of Care Diagnostics Market Size and Forecast, By Sample (2020 to 2031F) (In USD Billion)
Table 10: China Point of Care Diagnostics Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)
Table 11: China Point of Care Diagnostics Market Size and Forecast By Technology/Platform (2020 to 2031F) (In USD Billion)
Table 12: China Point of Care Diagnostics Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)
Table 13: Japan Point of Care Diagnostics Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)
Table 14: Japan Point of Care Diagnostics Market Size and Forecast By Technology/Platform (2020 to 2031F) (In USD Billion)
Table 15: Japan Point of Care Diagnostics Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)
Table 16: India Point of Care Diagnostics Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)
Table 17: India Point of Care Diagnostics Market Size and Forecast By Technology/Platform (2020 to 2031F) (In USD Billion)
Table 18: India Point of Care Diagnostics Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)
Table 19: Australia Point of Care Diagnostics Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)
Table 20: Australia Point of Care Diagnostics Market Size and Forecast By Technology/Platform (2020 to 2031F) (In USD Billion)
Table 21: Australia Point of Care Diagnostics Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)
Table 22: South Korea Point of Care Diagnostics Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)
Table 23: South Korea Point of Care Diagnostics Market Size and Forecast By Technology/Platform (2020 to 2031F) (In USD Billion)
Table 24: South Korea Point of Care Diagnostics Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)
Table 25: Competitive Dashboard of top 5 players, 2025
Figure 2: Asia-Pacific Point of Care Diagnostics Market Share By Country (2025)
Figure 3: China Point of Care Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 4: Japan Point of Care Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 5: India Point of Care Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 6: Australia Point of Care Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 7: South Korea Point of Care Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 8: Porter's Five Forces of Global Point of Care Diagnostics Market
Point of Care Diagnostics Market Research FAQs
Related Reports
One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. License information
One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. License information
Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. License information
All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). License information
Safe and Secure SSL Encrypted
Quick Contacts
Want to customize this report?
We offer 10% Free Customization at the time of purchase
Get Free Customization
Our Clients
Budget constraints? Get in touch with us for special pricing
Request DiscountOrder Detail
- Order Placed (23 September, 2026)
- Notify To Team (23 September, 2026)
- Report updation (24 September, 2026)
- Report Quality Check (24 September, 2026)
- Report Dispatch (25 September, 2026)
- Hard Copy
Recently Viewed Products
Asia-Pacific Point of Care Diagnostics Market Outlook, 2031
We are friendly and approachable, give us a call.